KR102408272B1 - 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제 - Google Patents

베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제 Download PDF

Info

Publication number
KR102408272B1
KR102408272B1 KR1020227004041A KR20227004041A KR102408272B1 KR 102408272 B1 KR102408272 B1 KR 102408272B1 KR 1020227004041 A KR1020227004041 A KR 1020227004041A KR 20227004041 A KR20227004041 A KR 20227004041A KR 102408272 B1 KR102408272 B1 KR 102408272B1
Authority
KR
South Korea
Prior art keywords
compound
methyl
oxa
azaspiro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227004041A
Other languages
English (en)
Korean (ko)
Other versions
KR20220025128A (ko
Inventor
투이-안 트랜
쿠엔-쿠엔 도
브렛 울먼
씨. 블랙번 앤서니
나구라 마이코
Original Assignee
아레나 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아레나 파마슈티칼스, 인크. filed Critical 아레나 파마슈티칼스, 인크.
Publication of KR20220025128A publication Critical patent/KR20220025128A/ko
Application granted granted Critical
Publication of KR102408272B1 publication Critical patent/KR102408272B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
KR1020227004041A 2016-06-06 2017-06-05 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제 Active KR102408272B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346293P 2016-06-06 2016-06-06
US62/346,293 2016-06-06
KR1020197000005A KR20190026731A (ko) 2016-06-06 2017-06-05 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제
PCT/US2017/035867 WO2017214002A1 (en) 2016-06-06 2017-06-05 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000005A Division KR20190026731A (ko) 2016-06-06 2017-06-05 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제

Publications (2)

Publication Number Publication Date
KR20220025128A KR20220025128A (ko) 2022-03-03
KR102408272B1 true KR102408272B1 (ko) 2022-06-10

Family

ID=59067920

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227004041A Active KR102408272B1 (ko) 2016-06-06 2017-06-05 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제
KR1020197000005A Withdrawn KR20190026731A (ko) 2016-06-06 2017-06-05 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197000005A Withdrawn KR20190026731A (ko) 2016-06-06 2017-06-05 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제

Country Status (29)

Country Link
US (5) US20190284200A1 (https=)
EP (1) EP3464292B8 (https=)
JP (3) JP6771246B2 (https=)
KR (2) KR102408272B1 (https=)
CN (1) CN109563103B (https=)
AR (1) AR108772A1 (https=)
AU (2) AU2017278102B2 (https=)
CA (1) CA3026024C (https=)
CL (1) CL2018003451A1 (https=)
CO (1) CO2019000041A2 (https=)
CR (1) CR20180595A (https=)
DK (1) DK3464292T3 (https=)
EA (1) EA201892817A1 (https=)
EC (1) ECSP19001018A (https=)
ES (1) ES2929737T3 (https=)
IL (2) IL289378B (https=)
MA (2) MA44037B1 (https=)
MX (2) MX387995B (https=)
MY (1) MY195982A (https=)
NI (1) NI201800130A (https=)
NZ (1) NZ749202A (https=)
PE (1) PE20190445A1 (https=)
PH (1) PH12018502550B1 (https=)
PT (1) PT3464292T (https=)
SG (1) SG11201810788QA (https=)
TN (1) TN2018000391A1 (https=)
TW (2) TWI752963B (https=)
UA (1) UA125120C2 (https=)
WO (1) WO2017214002A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CN111699189B (zh) * 2017-12-06 2025-02-18 艾尼纳制药公司 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20250127773A1 (en) * 2021-08-09 2025-04-24 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure
JP2024532227A (ja) * 2021-08-26 2024-09-05 アリーナ ファーマシューティカルズ， インコーポレイテッド 腎嚢胞性疾患および心腎症候群の処置または予防のためのベータ３アドレナリン作動性受容体のモジュレーター
US20240409548A1 (en) * 2021-10-06 2024-12-12 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
WO2023154499A1 (en) * 2022-02-14 2023-08-17 Biogen Ma Inc. Emopamil-binding protein inhibitors and uses thereof
CN114539103B (zh) * 2022-03-21 2023-04-07 佳木斯黑龙农药有限公司 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法
CN116178220A (zh) * 2022-12-13 2023-05-30 爱斯特（成都）生物制药股份有限公司 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065895A1 (fr) 1998-06-18 1999-12-23 Sanofi-Synthelabo Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3028340C2 (de) * 1980-07-25 1987-02-05 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US5254595A (en) 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
FR2751646B1 (fr) 1996-07-23 1999-01-22 Sanofi Sa Phenoxypropanolamine a action antagoniste beta3-adrenergique
WO1998027080A1 (en) 1996-12-19 1998-06-25 Agrevo Uk Limited Chromones useful as fungicides
JP4782342B2 (ja) * 1999-12-17 2011-09-28 サノフィ−アベンティス フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
DE20204129U1 (de) 2002-03-15 2002-07-25 Wella Ag, 64295 Darmstadt Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
US20080255134A1 (en) * 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
US8722851B2 (en) 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
WO2010051497A1 (en) 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
EP2498600B1 (en) 2008-10-31 2016-03-02 Pain Therapeutics, Inc. Filamin a-binding anti-inflammatory analgesic
US20110230493A1 (en) * 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
EP2563764B1 (en) * 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
AU2011279845B8 (en) * 2010-07-23 2014-11-20 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
JP2012092038A (ja) 2010-10-26 2012-05-17 F Hoffmann La Roche Ag 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤
ES2716049T3 (es) 2012-07-13 2019-06-07 Pain Therapeutics Inc Un método para inhibir la fosforilación de tau
JP6566867B2 (ja) 2012-07-13 2019-08-28 ペイン セラピューティクス インコーポレイテッド 生きている患者でのアルツハイマー病アッセイ
GB201405359D0 (en) 2014-03-25 2014-05-07 Univ Liverpool Synthetic process
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
CN111699189B (zh) * 2017-12-06 2025-02-18 艾尼纳制药公司 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065895A1 (fr) 1998-06-18 1999-12-23 Sanofi-Synthelabo Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
TN2018000391A1 (en) 2020-06-15
NZ749202A (en) 2022-07-01
MA44037B1 (fr) 2020-03-31
US20190284200A1 (en) 2019-09-19
EP3464292B1 (en) 2022-09-21
AU2021206809A1 (en) 2021-08-12
MX2018015124A (es) 2019-09-09
PH12018502550B1 (en) 2023-01-27
AU2017278102B2 (en) 2021-04-29
MX2021014043A (es) 2022-02-21
JP2022089984A (ja) 2022-06-16
US20190389875A1 (en) 2019-12-26
MA45150A (fr) 2021-05-05
IL263148A (en) 2018-12-31
JP2020203945A (ja) 2020-12-24
EA201892817A1 (ru) 2019-06-28
JP6771246B2 (ja) 2020-10-21
IL289378A (en) 2022-02-01
EP3464292A1 (en) 2019-04-10
CA3026024C (en) 2024-07-02
MA44037A1 (fr) 2019-05-31
NI201800130A (es) 2019-06-13
TWI784840B (zh) 2022-11-21
US10927123B2 (en) 2021-02-23
MY195982A (en) 2023-02-27
EP3464292B8 (en) 2022-10-26
US11560386B2 (en) 2023-01-24
UA125120C2 (uk) 2022-01-12
US20210340154A1 (en) 2021-11-04
US10662200B2 (en) 2020-05-26
US10479797B2 (en) 2019-11-19
AU2021206809B2 (en) 2023-01-05
ES2929737T3 (es) 2022-12-01
CO2019000041A2 (es) 2019-04-30
CN109563103B (zh) 2022-05-27
DK3464292T3 (da) 2022-10-31
CL2018003451A1 (es) 2019-02-22
US20190292196A1 (en) 2019-09-26
PE20190445A1 (es) 2019-03-29
JP2019518079A (ja) 2019-06-27
IL263148B (en) 2022-02-01
IL289378B (en) 2022-09-01
JP7083087B2 (ja) 2022-06-10
CR20180595A (es) 2019-04-09
ECSP19001018A (es) 2019-02-28
KR20190026731A (ko) 2019-03-13
AR108772A1 (es) 2018-09-26
WO2017214002A1 (en) 2017-12-14
JP7449329B2 (ja) 2024-03-13
TW202237619A (zh) 2022-10-01
SG11201810788QA (en) 2018-12-28
MX387995B (es) 2025-03-19
PT3464292T (pt) 2022-11-15
CA3026024A1 (en) 2017-12-14
AU2017278102A1 (en) 2019-01-17
US20200270264A1 (en) 2020-08-27
TWI752963B (zh) 2022-01-21
PH12018502550A1 (en) 2019-11-04
KR20220025128A (ko) 2022-03-03
CN109563103A (zh) 2019-04-02
BR112018075201A2 (pt) 2019-03-19
TW201803877A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
KR102408272B1 (ko) 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제
JP7357617B2 (ja) 心不全およびそれに関連する障害の治療または予防に有用なβ－３アドレナリン受容体のモジュレーター
HK40004811A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
HK40004811B (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
EA041181B1 (ru) Модулятор бета-3-адренергического рецептора, применяемый для лечения или предотвращения связанных с данным рецептором расстройств
BR112018075201B1 (pt) Compostos moduladores do receptor beta-3 adrenérgico e composição farmacêutica que os compreende, seus usos e método de preparação da referida composição
HK40039344A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
HK40039344B (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
HK40006318A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
HK40006318B (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4